World Entertainment News Network
Drugs currently being used to treat breast cancer patients could also prove effective in the fight against lung cancer. Scientists at the Institute of Cancer Research in London discovered breast cancer drugs called PARP inhibitors worked in up to half of NSCLC tumours. NSCLC (Non-small-cell lung cancer) is the world's biggest cancer killer and the most common type of the disease. Study author Dr Chris Lord said: "This study suggests that PARP inhibitors, treatments already in clinical trials to treat breast and ovarian cancer, could also be a promising treatment for patients with certain forms of lung cancer. Lung cancer is hard to treat and unfortunately has very poor survival, so there's an urgent need to find new treatments."
Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.